Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Published:2016-11 Issue:11 Volume:27 Page:2059-2066
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Vuylsteke P.,Huizing M.,Petrakova K.,Roylance R.,Laing R.,Chan S.,Abell F.,Gendreau S.,Rooney I.,Apt D.,Zhou J.,Singel S.,Fehrenbacher L.

Funder

F. Hoffmann-La Roche Ltd/Genentech Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/11/2059/19446601/mdw320.pdf

Reference17 articles.

1. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Breast,2014

2. Breast cancer version 2.2015;Gradishar;J Natl Compr Canc Netw,2015

3. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer;Miller;J Clin Oncol,2011

4. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer;Lauring;J Natl Compr Canc Netw,2013

5. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer;Yang;Cancer Treat Rev,2016

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

2. Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment;Discover Nano;2024-09-07

3. Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Current Cancer Drug Targets;2024-09

4. Rational Design of a Novel 6H-Benzo[c]chromen Series as Selective PI3Kα Inhibitors;Journal of Medicinal Chemistry;2024-08-19

5. Significance of phosphoinositide 3-kinase inhibitors in advanced breast cancer: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-08-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3